[go: up one dir, main page]

EP3914265A4 - Immunothérapie de lymphocytes b - Google Patents

Immunothérapie de lymphocytes b Download PDF

Info

Publication number
EP3914265A4
EP3914265A4 EP20745872.0A EP20745872A EP3914265A4 EP 3914265 A4 EP3914265 A4 EP 3914265A4 EP 20745872 A EP20745872 A EP 20745872A EP 3914265 A4 EP3914265 A4 EP 3914265A4
Authority
EP
European Patent Office
Prior art keywords
lymphocyte immunotherapy
immunotherapy
lymphocyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20745872.0A
Other languages
German (de)
English (en)
Other versions
EP3914265A1 (fr
Inventor
Mark C. Poznansky
Ruxandra F. SIRBULESCU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Holy Cross Hospital Inc
Original Assignee
General Hospital Corp
Holy Cross Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Holy Cross Hospital Inc filed Critical General Hospital Corp
Priority claimed from PCT/US2020/014836 external-priority patent/WO2020154534A1/fr
Publication of EP3914265A1 publication Critical patent/EP3914265A1/fr
Publication of EP3914265A4 publication Critical patent/EP3914265A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP20745872.0A 2019-01-23 2020-01-23 Immunothérapie de lymphocytes b Pending EP3914265A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962795629P 2019-01-23 2019-01-23
US201962837765P 2019-04-24 2019-04-24
PCT/US2020/014836 WO2020154534A1 (fr) 2019-01-23 2020-01-23 Immunothérapie de lymphocytes b

Publications (2)

Publication Number Publication Date
EP3914265A1 EP3914265A1 (fr) 2021-12-01
EP3914265A4 true EP3914265A4 (fr) 2023-02-01

Family

ID=78232398

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20745872.0A Pending EP3914265A4 (fr) 2019-01-23 2020-01-23 Immunothérapie de lymphocytes b

Country Status (2)

Country Link
EP (1) EP3914265A4 (fr)
CN (1) CN113677354A (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115393351B (zh) * 2022-10-27 2023-01-24 北京大学第三医院（北京大学第三临床医学院） 一种基于朗格汉斯细胞判断角膜免疫状态的方法及装置
CN119290541B (zh) * 2024-12-13 2025-04-04 天津医科大学总医院空港医院 一种淋巴组织中b细胞亚群的检测方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019178613A1 (fr) * 2018-03-16 2019-09-19 Immusoft Corporation Lymphocytes b génétiquement modifiées pour sécréter de la follistatine et leurs méthodes d'utilisation pour traiter des maladies, des états, des troubles liés à la follistatine et pour améliorer la croissance et la résistance musculaires

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2673158T3 (es) * 2004-02-09 2018-06-20 Mitsubishi Tanabe Pharma Corporation Nuevo agente terapéutico para la esclerosis lateral amiotrófica (ELA) o enfermedad atribuible a ELA
US7695712B2 (en) * 2005-04-18 2010-04-13 Actx, Inc. Recovery of tissue function following administration of B cells to injured tissue
US20100028296A1 (en) * 2005-05-02 2010-02-04 Chavez Raymond A Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
CA2722184A1 (fr) * 2008-04-25 2009-10-29 Duke University Lymphocytes b regulateurs et leurs applications
WO2011147622A1 (fr) * 2010-05-26 2011-12-01 Deutsches Rheuma-Forschungszentrum Berlin Lymphocytes b naïfs présentateurs d'antigènes modifiés pour la suppression immunitaire et procédé de fabrication desdites cellules modifiées

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019178613A1 (fr) * 2018-03-16 2019-09-19 Immusoft Corporation Lymphocytes b génétiquement modifiées pour sécréter de la follistatine et leurs méthodes d'utilisation pour traiter des maladies, des états, des troubles liés à la follistatine et pour améliorer la croissance et la résistance musculaires

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. RAY ET AL: "A Novel IL-10-Independent Regulatory Role for B Cells in Suppressing Autoimmunity by Maintenance of Regulatory T Cells via GITR Ligand", THE JOURNAL OF IMMUNOLOGY, vol. 188, no. 7, 1 April 2012 (2012-04-01), pages 3188 - 3198, XP055034451, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1103354 *
BODHANKAR SHEETAL ET AL: "IL-10-producing B-cells limit CNS inflammation and infarct volume in experimental stroke", vol. 28, no. 3, 1 September 2013 (2013-09-01), US, pages 375 - 386, XP055960801, ISSN: 0885-7490, Retrieved from the Internet <URL:https://link.springer.com/content/pdf/10.1007/s11011-013-9413-3.pdf> DOI: 10.1007/s11011-013-9413-3 *
MILO RON ET AL: "Therapies for multiple sclerosis targeting B cells", vol. 60, no. 2, 1 April 2019 (2019-04-01), CR, pages 87 - 98, XP055960892, ISSN: 0353-9504, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509632/pdf/CroatMedJ_60_0087.pdf> DOI: 10.3325/cmj.2019.60.87 *
PENNATI ANDREA ET AL: "Adoptive transfer of IL-10+regulatory B cells decreases myeloid-derived macrophages in the central nervous system in a transgenic amyotrophic lateral sclerosis model", CELLULAR & MOLECULAR IMMUNOLOGY, NATURE PUBLISHING GROUP UK, LONDON, vol. 15, no. 7, 8 January 2018 (2018-01-08), pages 727 - 730, XP036854777, ISSN: 1672-7681, [retrieved on 20180108], DOI: 10.1038/CMI.2017.152 *
See also references of WO2020154534A1 *

Also Published As

Publication number Publication date
CN113677354A (zh) 2021-11-19
EP3914265A1 (fr) 2021-12-01

Similar Documents

Publication Publication Date Title
IL280780A (en) Anti-TIGIT antibodies
SG11202106214YA (en) Novel anti-ccr8 antibody
IL280013A (en) Anti-IL36R antibodies
IL291068A (en) Anti-cd73 antibodies
IL279352A (en) IL-11RA antibodies
IL289112A (en) Antibodies against tigit
SG11202108141VA (en) Novel cd40-binding antibodies
IL278010A (en) Antibodies to galectin 10
GB201905150D0 (en) Ant-ige antibodies
GB202110263D0 (en) Anti-btla antibodies
IL277030A (en) Antibodies
IL280239B1 (en) Enhanced clotting antibodies
IL284584A (en) Anti-tigit antibodies
IL323170A (en) Antibodies against KLRG1
GB2581174B (en) Antibodies against hEPCR
EP4025204A4 (fr) Immunothérapie anticancéreuse
IL276816A (en) Antibody purification
EP3914265A4 (fr) Immunothérapie de lymphocytes b
IL292799A (en) Anti-siglec-9 antibody molecules
GB201900732D0 (en) Antibodies
GB201806084D0 (en) Antibodies
GB201917480D0 (en) Antibodies
IL289160A (en) Anti-angpt2 antibodies
GB2598698B (en) Affinity-maturated anti-ASICIa antibodies
GB201919280D0 (en) Antibodies

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210817

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HOLY CROSS HOSPITAL, INC.

Owner name: THE GENERAL HOSPITAL CORPORATION

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/0781 20100101ALI20220920BHEP

Ipc: A61P 25/28 20060101ALI20220920BHEP

Ipc: A61K 35/12 20150101AFI20220920BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20230105

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/0781 20100101ALI20221223BHEP

Ipc: A61P 25/28 20060101ALI20221223BHEP

Ipc: A61K 35/12 20150101AFI20221223BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240614

17Q First examination report despatched

Effective date: 20240626